Table 1.
Randomized Controlled Trials of Ketamine in Mood Disorders, OCD and PTSD
| Study | Route | Dose | Treatment Schedule |
Diagnosis | N | Design | 1° Outcome | Response ratea |
|---|---|---|---|---|---|---|---|---|
| Berman et al., 2000 | IV | 0.5 mg/kg | Single | MDD | 7 | Crossover | HAM-D | 50% |
| Zarate et al., 2006 | IV | 0.5 mg/kg | Single | MDD (TR) | 17 | Crossover | HAM-D | 71% |
| Lapidus et al., 2014 | IN | 0.5 mg/kg | Single | MDD (TR) | 18 | Crossover | MADRS | 44% |
| Murrough et al., 2013 | IV | 0.5 mg/kg | Single | MDD (TR) | 72 | Parallel-arm | MADRS | 64% |
| Valentine et al., 2011 | IV | 0.5 mg/kg | Single | MDD | 10 | Crossover | HAM-D | -- |
| Diazgranados et al., 2010 | IV | 0.5 mg/kg | Single | BPD (TR) | 18 | Crossover | MADRS | 56% |
| Zarate et al., 2012 | IV | 0.5 mg/kg | Single | BPD (TR) | 15 | Crossover | MADRS | 79% |
| Rodriguez et al., 2013 | IV | 0.5 mg/kg | Single | OCD | 15 | Crossover | Y-BOCS | 50% b |
| Feder et al., 2015 | IV | 0.5 mg/kg | Single | PTSD | 35 | Crossover | IES-R | -- |
a
Response rate was defined as reduction ≥ 50% in primary outcome measure, unless otherwise noted.
b
Response rate was defined as reduction ≥ 35% of primary outcome measure.
IV=Intravenous; IM=Intramuscular; IN=Intranasal; MDD=Major Depressive Disorder; TR=Treatment Resistant; BPD=Bipolar Disorder; OCD=Obsessive Compulsive Disorder; PTSD=Post Traumatic Stress Disorder; HAM-D=Hamilton Depression Rating Scale; MADRS=Montgomery– Asberg Depression Rating Scale; RCT, Randomized, controlled trial; Y-BOCS=Yale-Brown Obsessive-Compulsive Scale; IES-R=Impact of Event Scale–Revised